Compare Fubotv Inc (FUBO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs BIO-TECHNE Corp — how do they compare? Fubotv Inc trades at $10.46 (market cap $302.39M), while BIO-TECHNE Corp trades at $71.55 (market cap $11.14B). The key difference: BIO-TECHNE Corp is far larger — about 36.8× Fubotv Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | TECH | |
|---|---|---|
Market Cap | $302.39M | $11.14B |
Sector | Technology | Health |
52-Week High | $54.72 | $71.48 |
52-Week Low | $8.09 | $43.31 |
Enterprise Value | $472.81M | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.54, down 2.95% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $172.25 million in 2024, but revenue grew to $1.62 billion, and profitability improved significantly in 2025 with a net income margin of 7.61%. Valuation ratios appear low, with a P/E of 2.67 and P/S of 0.21. Recent news highlights the appointment of a new CEO from Disney, sparking investor optimism about future growth.
The outlook is mixed; low valuations and a path to profitability present opportunity, but persistent cash flow challenges and high debt levels pose significant risks. Analyst consensus is a Buy with a $16.25 price target, suggesting substantial upside if the new leadership can execute on growth and monetization strategies effectively.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
